Centogene joins forces with insilico medicine for niemann-pick disease type c (npc) target discovery, applying artificial intelligence (ai) to accelerate orphan drug development

Cambridge, mass. and rostock, germany, and berlin, jan. 20, 2022 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on generating data-driven insights to diagnose, understand and treat rare diseases, and insilico medicine, an end-to-end artificial intelligence (ai) -driven drug discovery company, today announced a research and development collaboration to accelerate the discovery of novel therapeutic targets for niemann-pick disease type c. the duration of the research collaboration will initially last 20 weeks.
CNTG Ratings Summary
CNTG Quant Ranking